Stocks Health care ANIK
NASDAQ · Health careAnika Therapeutics, Inc. (ANIK)
Anika Therapeutics, Inc. brought in $123.4M of revenue over the twelve months to September 30, 2026, up 9.4% from a year earlier. It posted a net loss of $1.8M. Operating cash flow minus capital spending left $4.4M of free cash flow in fiscal 2025. At September 30, 2026 it held $45M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 6, 2026.
Key facts about Anika Therapeutics, Inc.
- Net worth
- Anika Therapeutics, Inc. has a market value (market cap) of $193.5M at the latest share price, and shareholders' equity of $137.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $112.8M (-5.9% year on year), with a net loss of $10.9M. Over the 12 months to September 30, 2026: revenue $123.4M, net loss $1.8M.
- Cash flow
- In fiscal 2025 operations brought in $11.2M of cash; after $6.8M of capital spending, free cash flow was $4.4M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 6, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Anika Therapeutics, Inc.'s next report is expected around January 7, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Anika Therapeutics, Inc. does
Anika Therapeutics, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker ANIK.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $112.8M | -$10.9M | -$0.76 | $4.4M |
| 2024 | $119.9M | -$56.4M | -$3.83 | -$2.3M |
| 2023 | $120.8M | -$82.7M | -$5.64 | -$7.2M |
| 2022 | $113.8M | -$14.9M | -$1.02 | -$3.1M |
| 2021 | $147.8M | $4.1M | $0.28 | $3.3M |
| 2020 | $130.5M | -$24M | -$1.69 | $11.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ANIK ranks in Health care
Latest SEC filings
What Anika Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 10% to $30.6M versus the same quarter last year; diluted EPS -$0.02 versus -$0.16.
- November 6, 2026
- July 31, 2026Passive stake changed SCHEDULE 13G/A
- July 29, 2026
- July 29, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 16% to $32.6M versus the same quarter last year; diluted EPS $0.24 versus -$0.28.
- July 29, 2026
- July 17, 2026Passive stake changed SCHEDULE 13G/A
- July 14, 2026
- June 23, 2026
- June 8, 2026Additional proxy material DEFA14A
What is ANIK worth? A DCF from its reported cash flow
Insider trades
What the people running Anika Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 4, 2026 | Fischetti Gary PDirector | Bought | 1,000 | $20.3K |
| August 3, 2026 | Fischetti Gary PDirector | Bought | 1,000 | $20.7K |
| June 18, 2026 | Conley Sheryl LDirector | Received as pay | 10,402 | - |
| June 18, 2026 | Capper Joseph HDirector | Received as pay | 10,402 | - |
| June 18, 2026 | Richard StephenDirector | Received as pay | 10,402 | - |
| June 18, 2026 | Henneman John B IIIDirector | Received as pay | 10,402 | - |
| June 18, 2026 | Fischetti Gary PDirector | Received as pay | 10,402 | - |
| June 3, 2026 | Griffin Stephen D.President and CEO, Director | Exercised options | 12,840 | - |
Who owns ANIK
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Caligan Partners LP13D, may seek influence with 1 related filers | 9.95% | January 27, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 133 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 1,449,671 | -145,222 |
| Caligan Partners LP | 1,435,130 | 0 |
| Morgan Stanley | 614,320 | -257,746 |
| Vanguard Capital Management LLC | 572,113 | -33,664 |
| Aqr Capital Management LLC | 559,846 | +287,577 |
| Boothbay Fund Management, LLC | 529,640 | +137 |
| Renaissance Technologies LLC | 481,417 | -20,800 |
| Dimensional Fund Advisors LP | 451,095 | -7,752 |
| Capital Management Corp | 448,474 | +753 |
| Deutsche Bank AG\ | 353,552 | +378 |
| Geode Capital Management, LLC | 331,577 | +1,526 |
| State Street Corp | 311,896 | -34,196 |
| Two Sigma Investments, LP | 252,964 | +16,844 |
| D. E. Shaw & Co., Inc. | 245,066 | +15,270 |
| Goldman Sachs Group Inc | 237,722 | +19,844 |
| Jacobs Levy Equity Management, Inc | 217,530 | -48,097 |
| Nuveen, LLC | 156,538 | +35,821 |
| Quantinno Capital Management LP | 155,257 | +29,431 |
| UBS Group AG | 145,816 | +12,742 |
| Man Group plc | 140,712 | +16,419 |
Insiders
9 insiders reported holding 657,774 shares in total, about $9.5M at the last price.
| Holder | Shares |
|---|---|
| Blanchard Cheryl RDirector | 258,788 |
| Colleran DavidEVP, General Counsel, Corp Sec | 67,570 |
| Henneman John B IIIDirector | 65,273 |
| Richard StephenDirector | 58,273 |
| Fischetti Gary PDirector | 54,015 |
| Conley Sheryl LDirector | 52,970 |
| Griffin Stephen D.President and CEO, Director | 45,973 |
| Capper Joseph HDirector | 30,805 |
| McLeod IanSVP, CAO & Treasurer | 24,107 |
Questions about ANIK
What does Anika Therapeutics, Inc. do?
Anika Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as ANIK. Its shares trade on NASDAQ under the ticker ANIK.
What is Anika Therapeutics, Inc.'s net worth?
Anika Therapeutics, Inc. has a market value (market cap) of $193.5M at the latest share price, and shareholders' equity of $137.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Anika Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $1.8M on revenue of $123.4M.
How much revenue does Anika Therapeutics, Inc. make?
Over the twelve months to September 30, 2026 Anika Therapeutics, Inc. reported revenue of $123.4M. That is 9.4% more than a year earlier.
When did Anika Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 6, 2026. It covers the period to September 30, 2026.
When is Anika Therapeutics, Inc.'s next earnings report?
Anika Therapeutics, Inc.'s next report is expected around January 7, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ANIK with
Follow ANIK
Get an email when Anika Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Anika Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.